3150 Almaden Expressway
Suite 250
San Jose, CA 95118
United States
408 708 9808
https://www.anixa.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 4
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Amit Kumar Ph.D. | CEO, Chairman & Co-Chair of CBAB | 1,18M | 38,78k | 1964 |
Mr. Michael J. Catelani CPA, MBA | President, COO, CFO & Corporate Secretary | 724,94k | S.O. | 1967 |
Mr. John Roop | Senior Vice President of Engineering | 252,73k | S.O. | 1950 |
Dr. Pamela D. Garzone Ph.D. | Chief Development Officer & Chair Breast Cancer Clinical Advisory Board | S.O. | S.O. | 1955 |
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
L’ISS Governance QualityScore de Anixa Biosciences, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..